Delta-8 and Delta-9 THC: Similar Chemistry, Different Potency and Risks

Delta-8 THC and delta-9 THC are closely related cannabinoids that can both produce intoxication, but they are not interchangeable. The main differences involve their chemical structure, typical potency, legal treatment, product quality and the strength of the evidence supporting their use.

Delta-9 THC is the best-known intoxicating compound in cannabis. Delta-8 THC occurs naturally in the plant in much smaller quantities and is commonly produced by converting hemp-derived cannabidiol (CBD) into concentrated delta-8 THC. Consumers considering either product should understand that “hemp-derived” does not mean non-intoxicating or risk-free.

What is delta-8 THC?

Delta-8 tetrahydrocannabinol is a naturally occurring cannabinoid and a structural isomer of delta-9 THC, meaning the two compounds contain the same atoms arranged somewhat differently. That small chemical difference affects how strongly they interact with cannabinoid receptors in the body.

Natural hemp contains only a small amount of delta-8 THC. As a result, many commercial products are made by chemically converting CBD into delta-8 THC. The U.S. Food and Drug Administration’s consumer guidance on delta-8 THC notes that these processes can create unwanted by-products or leave behind contaminants, particularly when manufacturing is not carefully controlled.

Delta-8 products are sold as gummies, candies, beverages, vape products, tinctures and other preparations. Their effects are generally described as less intense than those of comparable amounts of delta-9 THC, but the difference is not consistent for every person or product. Dose, route of administration, tolerance and product purity all matter.

What is delta-9 THC?

Delta-9 THC is the primary intoxicating cannabinoid in most marijuana products. It is responsible for the “high” associated with cannabis and can affect perception, memory, coordination, reaction time, mood and appetite.

Delta-9 THC is available in numerous forms, including dried cannabis, concentrates, edibles, vape products, tinctures and infused beverages. Some prescription medicines contain dronabinol, a synthetic form of delta-9 THC. The FDA has approved dronabinol products for specific uses, including chemotherapy-related nausea and vomiting and appetite loss associated with AIDS—not for general treatment of pain, anxiety or sleep problems. Those approved medicines have undergone evaluation for quality, safety and effectiveness; commercial cannabis products have not necessarily received the same review.

Research on cannabis and THC has explored possible effects involving pain, nausea, appetite, muscle spasticity and other symptoms. However, evidence for one THC product or formulation cannot automatically be applied to another. Claims that an over-the-counter delta-8 or delta-9 product treats a medical condition should be viewed cautiously.

How the two compounds affect the body

Both delta-8 and delta-9 THC act primarily as partial agonists at CB1 receptors, which are abundant in the brain and central nervous system. They also interact with CB2 receptors and other components of the endocannabinoid system. A peer-reviewed review of delta-8 THC pharmacology describes delta-8 as having cannabis-like effects in both human and animal research.

Delta-8 generally appears to have lower potency than delta-9 THC in many measures of activity, which may help explain why users often report a milder intoxicating effect. That does not make delta-8 non-psychoactive or automatically safer. Controlled human research remains limited, and effects can vary substantially depending on the dose and how the product is consumed.

Edibles deserve particular caution. Their effects may take longer to appear and can last longer than inhaled products, increasing the risk that someone will consume more before the initial dose has fully taken effect.

Legal status is complicated

The 2018 federal Farm Bill defined hemp based on its delta-9 THC concentration—no more than 0.3% by dry weight. Because the law did not originally address every intoxicating cannabinoid in the same way, some manufacturers and courts treated certain hemp-derived delta-8 products as falling outside federal marijuana restrictions. That interpretation did not make delta-8 products FDA-approved, nor did it create uniform legality across the country.

State, territorial and tribal laws may prohibit delta-8 THC, restrict its sale or regulate it differently from marijuana. Federal law is also changing: a 2025 amendment to the statutory hemp definition is scheduled to take effect on November 12, 2026, and will use a broader total-THC framework while excluding certain synthetic or intoxicating hemp-derived cannabinoid products. Consumers should check the current rules in their jurisdiction rather than relying on a product label or a retailer’s description.

Product quality and safety concerns

Neither delta-8 nor delta-9 THC is harmless simply because it comes from cannabis or hemp. Potential short-term effects include impaired attention and coordination, dizziness, anxiety, panic, confusion, drowsiness, increased heart rate and—in some cases—paranoia or hallucinations. Driving or operating machinery after using either compound is unsafe.

Delta-8 products raise additional concerns because they are often manufactured outside the regulated cannabis systems that require testing. Labels may inaccurately state the amount of THC, and products may contain delta-9 THC, other cannabinoids, residual solvents, heavy metals or reaction by-products. In 2022, the FDA reported adverse events involving delta-8 products, including vomiting, tremor, anxiety, dizziness, confusion, hallucinations and loss of consciousness. The agency has not evaluated these products for safe use or effectiveness.

Children and pets are especially vulnerable to accidental exposure. Gummies, chocolates and other delta-8 edibles can resemble ordinary snacks, so all THC products should be stored securely and kept out of sight and reach.

Drug testing

Delta-8 THC can cause a positive result on many workplace and clinical cannabinoid screening tests. Standard screening methods often detect metabolites that are chemically similar to those produced after delta-9 THC use, rather than determining which THC isomer was consumed. The Substance Abuse and Mental Health Services Administration’s workplace-testing guidance explains that federal testing is designed to identify marijuana-related cannabinoid metabolites, while laboratory research has found substantial cross-reactivity from delta-8 metabolites.

Anyone subject to drug testing should assume that using delta-8 may lead to a positive cannabinoid screen. A confirmatory test may be able to distinguish compounds in some circumstances, but consumers should not rely on that possibility.

What consumers should consider

There is not enough high-quality evidence to conclude that delta-8 provides the same medical benefits as delta-9, or that it consistently causes fewer adverse effects. Reports of relaxation, sleepiness, appetite changes or pain relief are not the same as proof of clinical effectiveness.

• Do not assume that a hemp-derived product is non-intoxicating.
• Read the label, but recognize that labeling may not accurately reflect the contents.
• Avoid combining THC with alcohol, sedatives or other intoxicating substances.
• Do not drive or perform safety-sensitive tasks after using THC.
• Keep products away from children and animals.
• Ask a doctor or pharmacist about possible interactions with prescription medicines or existing health conditions.
• Seek urgent medical help for severe confusion, loss of consciousness, trouble breathing, chest pain, seizures or symptoms that feel dangerous.

The clearest distinction between delta-8 and delta-9 THC is not that one is safe and the other is dangerous. Both can impair judgment and coordination, and both require careful handling. Delta-8’s lower average potency may appeal to some consumers, but limited clinical data, inconsistent manufacturing and changing laws make caution essential. For medical treatment, products that have been evaluated and approved for a specific condition offer more reliable information about dose, quality and risk than unapproved cannabinoid products.